UroGen Pharma
URGN
UroGen Pharma (URGN) news
Recent news
Intragel Therapeutics and Urogen Pharma sign strategic collaboration and investment agreements to advance sustained-released investigational oncology therapies
AInvest Wire · Aug 20, 2026UroGen Pharma - to invest up to $7 mln in IntraGel equity securities
AInvest Wire · Aug 20, 2026UroGen Pharma - granted research license and exclusive options for three oncology products using SRGEL
AInvest Wire · Aug 20, 2026UroGen Pharma - granted exclusive option to buy worldwide rights to Tumocure
AInvest Wire · Aug 20, 2026UroGen Pharma Ltd: Oppenheimer raises target price to $60 from $50
Oppenheimer has raised its price target for UroGen Pharma (NASDAQ:URGN) to $60 from $50, while maintaining an Outperform rating . The adjustment follows updated sales forecasts for the company’s Jelmyto product, which is used in the treatment of bladder cancer. The firm now anticipates Jelmyto…
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.